tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.
![Tenax Therapeutics logo](/files/LOGO/34956-TENX.png)
Company profile
Ticker
TENX
Exchange
Website
CEO
Anthony DiTonno
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Life Newco, Inc. • PHPrecisionMed Inc. ...
IRS number
262593535
TENX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
13 Jun 24
DEFA14A
Additional proxy soliciting materials
24 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
14 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
Latest ownership filings
4
Stuart Rich
21 May 24
4
Christopher Thomas Giordano
21 May 24
SC 13G
S.H.N. Financial Investments Ltd.
20 Feb 24
SC 13G
CVI Investments, Inc.
16 Feb 24
SC 13G
Lind Global Fund II LP
15 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
3
LAWRENCE R HOFFMAN
12 Jan 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
13 Feb 23
SC 13D/A
Rich Stuart
9 Feb 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.55 mm | 12.55 mm | 12.55 mm | 12.55 mm | 12.55 mm | 12.55 mm |
Cash burn (monthly) | (no burn) | 155.45 k | 1.30 mm | (no burn) | 2.99 mm | 1.10 mm |
Cash used (since last report) | n/a | 601.00 k | 5.04 mm | n/a | 11.55 mm | 4.23 mm |
Cash remaining | n/a | 11.95 mm | 7.51 mm | n/a | 996.49 k | 8.31 mm |
Runway (months of cash) | n/a | 76.9 | 5.8 | n/a | 0.3 | 7.6 |
Institutional ownership, Q1 2024
32.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 982.00 k |
Total shares | 575.21 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 479.73 k | $840.00 k |
Stuart Rich | 95.48 k | $142.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 24 | Chrisopher Thomas Giordano | Stock Option Common Stock | Grant | Acquire A | No | No | 3.549 | 437 | 1.55 k | 437 |
17 May 24 | Stuart Rich | Stock Option Common Stock | Grant | Acquire A | No | No | 3.549 | 119 | 422.33 | 119 |